51 – 58 of 58
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2008
-
Mark
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
(
- Contribution to journal › Article
-
Mark
Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease
(
- Contribution to journal › Article
-
Mark
Central Role of Rho Kinase in Lipopolysaccharide-Induced Platelet Capture on Venous Endothelium.
(
- Contribution to journal › Article
-
Mark
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
(
- Contribution to journal › Article
- 2007
-
Mark
Residual platelet ADP reactivity after clopidogrel treatment is dependent on activation of both the unblocked P2Y(1) and the P2Y (12) receptor and is correlated with protein expression of P2Y (12).
(
- Contribution to journal › Article
-
Mark
Experimental and Clinical Studies on Platelet Receptors in Cardiovascular Disease
2007) In Lund University Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
- 2006
-
Mark
Fasudil, a Rho-kinase inhibitor, inhibits leukocyte adhesion in inflamed large blood vessels in vivo.
(
- Contribution to journal › Article
- 2005
-
Mark
Increased platelet purinergic sensitivity in peripheral arterial disease--a pilot study.
(
- Contribution to journal › Article